| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/16/2006 | WO2006016192A2 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 02/16/2006 | WO2006015775A2 Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders |
| 02/16/2006 | WO2005120476A3 Novel use of peptide compounds for treating amyotrophic lateral sclerosis |
| 02/16/2006 | WO2005105064A3 Modulators of frat-lrp interaction in the treatment of bone-related diseases |
| 02/16/2006 | WO2005097107A8 Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| 02/16/2006 | WO2005046738A3 Virucidal activities of cetylpyridinium chloride |
| 02/16/2006 | WO2004094373A3 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| 02/16/2006 | WO2004024095A3 ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
| 02/16/2006 | WO2003025129A3 Neurotransmission-associated proteins |
| 02/16/2006 | US20060036086 Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| 02/16/2006 | US20060036074 Bromodomain protein |
| 02/16/2006 | US20060035955 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 02/16/2006 | US20060035935 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/16/2006 | US20060035929 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 02/16/2006 | US20060035928 for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists |
| 02/16/2006 | US20060035927 administering to a patient suffering from bone disorder, a calcilytic compound, such as N-[(2R-Hydroxy-3-[(3-chloro-2-cyano)phenoxy-propyl]-1,1-dimethyl-2-(2-naphthyl)ethyl amine hydrochloride, in conjunction with an effective amount of an anti-resorptive agent. |
| 02/16/2006 | US20060035925 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/16/2006 | US20060035923 Overactive bladder treating drug |
| 02/16/2006 | US20060035918 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 02/16/2006 | US20060035914 Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| 02/16/2006 | US20060035911 Method of improved diuresis in individuals with impaired renal function |
| 02/16/2006 | US20060035904 Antineoplastic combinations |
| 02/16/2006 | US20060035876 Combination therapy of an SODm and a corticosteroid for prevention and/or treatment of inflammatory bone or joint disease |
| 02/16/2006 | US20060035875 Remedy for hormone-dependent cancer |
| 02/16/2006 | US20060035874 Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 02/16/2006 | US20060035873 Methods for inducing apolipoprotein e secretion |
| 02/16/2006 | US20060035867 For inhibition of bone metastases in prostate cancer patients |
| 02/16/2006 | US20060035856 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035855 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035851 Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair |
| 02/16/2006 | US20060035850 Plant thymidine kinases and their use |
| 02/16/2006 | US20060035840 Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia |
| 02/16/2006 | US20060035836 Treatment of acute coronary syndrome with an exendin |
| 02/16/2006 | US20060035833 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035832 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035831 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035830 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035825 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 02/16/2006 | US20060035814 Reagents and methods for smooth muscle therapies |
| 02/16/2006 | US20060035331 G-protein coupled receptors |
| 02/16/2006 | US20060035328 Artery-and vein-specific proteins and uses therefor |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035315 Transporters and ion channels |
| 02/16/2006 | US20060035303 JNK3 modulators and methods of use |
| 02/16/2006 | US20060035285 Method for identifying modulators of human orexin-2 receptor |
| 02/16/2006 | US20060035268 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 02/16/2006 | US20060035213 POSH nucleic acids, polypeptides and related methods |
| 02/16/2006 | US20060034957 Vitamin-containing system for stabilising the immune response of animals |
| 02/16/2006 | US20060034951 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/16/2006 | US20060034945 Composition for restoring damaged skin |
| 02/16/2006 | US20060034941 Organ preconditioning, arrest, protection, preservation and recovery |
| 02/16/2006 | US20060034932 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060034892 Composition for topical administration |
| 02/16/2006 | US20060034872 Compositions and methods for preventing abuse of orally administered medications |
| 02/16/2006 | US20060034864 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 02/16/2006 | US20060034837 Method and agents for the prevention, inhibition and therapy of cancers |
| 02/16/2006 | US20060034826 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 02/16/2006 | US20060034824 Pharmaceutical composition comprising carriers for products |
| 02/16/2006 | US20060034817 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase |
| 02/16/2006 | US20060034808 Amorphous cell delivery vehicle treated with physical/physicochemical stimuli |
| 02/16/2006 | US20060034799 Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs |
| 02/16/2006 | DE102004039326A1 Treatment of neurodegenerative diseases, specifically Alzheimer's disease and Down syndrome, uses a chemical/biological substance which inhibits fatty acid amide hydrolase without inhibiting cyclooxygenase-1 and/or 2 |
| 02/16/2006 | CA2576255A1 Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| 02/16/2006 | CA2575932A1 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases |
| 02/16/2006 | CA2575541A1 New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626084A1 Compositions and methods for the diagnosis of tumours |
| 02/15/2006 | EP1626058A1 Compositions and methods for the diagnosis of tumour |
| 02/15/2006 | EP1625847A1 Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine |
| 02/15/2006 | EP1625378A2 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| 02/15/2006 | EP1624895A2 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 02/15/2006 | EP1624893A2 Inhibitors of phosphodiesterases in infertility |
| 02/15/2006 | EP1624889A2 Compositions for inducing immune responses |
| 02/15/2006 | EP1624887A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes |
| 02/15/2006 | EP1624883A2 Compositions and methods related to production of erythropoietin |
| 02/15/2006 | EP1624878A1 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
| 02/15/2006 | EP1624752A2 Delivery of compounds with rehydrated blood cells |
| 02/15/2006 | EP1453835B1 Adenosine a 2a receptor antagonists |
| 02/15/2006 | EP1341533B1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 02/15/2006 | EP1268493B1 Phosphoramidate prodrugs |
| 02/15/2006 | EP1076562B1 Glucocorticoid receptor antagonists for the treatment of dementia |
| 02/15/2006 | EP1041985B1 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
| 02/15/2006 | EP1003550B1 Receptor specific transepithelial transport of therapeutics |
| 02/15/2006 | CN1735624A Phospholipid derivatives and process for the production there |
| 02/15/2006 | CN1735441A Combination for the treatment of ADHD |
| 02/15/2006 | CN1735435A Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 02/15/2006 | CN1735434A Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers |
| 02/15/2006 | CN1735416A Therapeutic combination |
| 02/15/2006 | CN1735415A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/15/2006 | CN1735412A Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 02/15/2006 | CN1735411A Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells |
| 02/15/2006 | CN1735410A Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells |
| 02/15/2006 | CN1735407A Methods of using and compositions comprising dopamine reuptake inhibitors |
| 02/15/2006 | CN1735344A Novel substituted benzimidazole dosage forms and method of using same |
| 02/15/2006 | CN1733722A Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 02/15/2006 | CN1733311A Process for preparing nanometer fiber for packaging medicine or growth factor |
| 02/15/2006 | CN1733308A Osmotic pump controlled release formulation containing two active constituents of medicine and process for preparing the same |
| 02/15/2006 | CN1733307A Antihypertensive combination of valsartan and calcium channel blocker |
| 02/15/2006 | CN1733306A Anticancer implantation agent containing blood vessel inhibitor and guanine similarities |
| 02/15/2006 | CN1733305A Anticancer implantation agent |